Ticker

Roku Inc (NASDAQ:ROKU) shares climbed almost 5% following the company’s release of fourth quarter 2025 results, which exceeded Wall Street expectations and...

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Thursday that two abstracts highlighting research on its lead drug candidate bezisterim (NE3107) have been accepted for presentation at the 2026 American College of Psychiatrists annual meeting in Bonita Springs, Florida. The abstracts, which focus on bezisterim's potential in Alzheimer's disease and Long COVID, will be presented as posters on February 18.

10am: Dow opens higher, Nasdaq dips US stocks have made another uneven start.  The Dow Jones and S&P 500 have opened 0.4% and 0.2% higher, but the Nasdaq...

In biotech, the most compelling investment stories often emerge where medical need, scientific differentiation, and timing intersect. BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW), a clinical-stage biopharmaceutical company with a market capitalization still measured in the tens of millions, is attempting exactly that by targeting what it believes is a root driver of neurodegeneration rather than merely treating symptoms.